Fulcrum Therapeutics Inc
NASDAQ:FULC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
US |
|
S
|
SSF Home Group Bhd
KLSE:SSF
|
MY |
|
F
|
Forafric Global PLC
NASDAQ:AFRI
|
GI |
|
S
|
SK Securities No.11 Special Purpose Acquisition Co
KOSDAQ:472230
|
KR |
|
Wilh Wilhelmsen Holding ASA
OTC:WLHSF
|
NO |
|
Novartis AG
F:NOT
|
CH |
|
S
|
SuNam Co Ltd
KOSDAQ:294630
|
KR |
Intrinsic Value
Is FULC undervalued or overvalued?
See the intrinsic value estimate for Fulcrum Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Fulcrum Therapeutics Does
Fulcrum Therapeutics is a drug development company focused on rare diseases that are driven by mistakes in gene control. It researches small-molecule medicines that try to turn specific genes on or off in a more precise way, with the goal of treating the underlying biology of the disease rather than just easing symptoms.
- Headquarters
- United States of America US
- Employees
- 55
- IPO date
- Jul 18, 2019
Revenue & Expenses Breakdown
Fulcrum Therapeutics Inc
Earnings Waterfall
Fulcrum Therapeutics Inc
The intrinsic value for Fulcrum Therapeutics Inc (FULC) under the Base Case is hidden USD.
Compared with the current market price of 3.77 USD, the stock appears hidden.